A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.
Condition(s) studied
Investigational drug(s) / intervention(s)
Synbiotic Dual Cap® Intervention: Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication.
Study summary
This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.
Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.
Eligibility
Primary outcome measure(s)
- Change in Overall Gastrointestinal Comfort — Baseline to Week 12
Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires - Change in Bowel Regularity — Baseline to Week 12
Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires - Change in Bloating — Baseline to Week 12
Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires - Change in Constipation — Baseline to Week 12
Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires - Change in Diarrhea — Baseline to Week 12
Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires - Change in Nausea — Baseline to Week 12
Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires - Change in Post-Meal Fullness Comfort — Baseline to Week 12
Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Citruslabs | Las Vegas | Nevada |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07946666 on ClinicalTrials.gov ↗ ← All trials in the USA